• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Point of Care Diagnostics Testing Market Analysis

    ID: MRFR/HC/9161-HCR
    120 Pages
    Rahul Gotadki
    October 2025

    Point of Care Diagnostics Testing Market By Product (Glucose Monitoring, Cardiometabolic Monitoring, Infectious Disease Testing, Coagulation Monitoring, Pregnancy & Fertility Testing, Hematology Testing, Cancer/Tumor Marker Testing, Urinalysis Testing, Cholesterol, Drugs-of-Abuse Testing), By End User (Hospitals & Clinics, Diagnostic Centers, Homecare/Self Testing), By Mode of Purchase...

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Point of Care Diagnostics Testing Market Infographic
    Purchase Options

    Market Analysis

    In-depth Analysis of Point of Care Diagnostics Testing Market Industry Landscape

    There has been a significant evolution in the market dynamics for Point-Of-Care Diagnostics/ Testing (POCT), completely transforming medical diagnostics. The term "point-of-care" refers to tests performed near patients, producing quick results that inform immediate clinical decisions. The need for faster and more convenient diagnostic solutions is one of the major factors driving growth in the POCT market. Traditionally, laboratory-based testing was characterized by lengthy procedures and delays before results were presented. Decentralization of healthcare services has played a key role in shaping the growth of the POCT market. As healthcare delivery models shift towards more community-based and patient-centric approaches, the demand for point-of-care testing has increased. POCT allows healthcare professionals to carry out diagnostic tests in various settings, including physician offices, clinics, pharmacies, or even at home. Technological advancements have been a driving force behind innovative POCT solutions. The development of portable and user-friendly testing platforms has been achieved through the miniaturization of diagnostic devices and the integration of microfluidics as well as biomolecules. Application of biosensors coupled with miniaturization techniques and microfluidic systems has enabled the production of portable and easy-to-use diagnostics. Market competition between established companies and newcomers has become fiercer, with both aiming to claim their part of the growing POCT market. Well-established diagnostic firms are expanding their portfolios on POCT through acquisitions or collaborations, while new startups bring about unique technologies along with devices. The emergence of the COVID-19 pandemic has greatly influenced these dynamics, resulting in changes within this sector. The global spread of the virus necessitates fast, widespread test administration to identify and control its spread, thus leading to an increase in demand for point-of-care test solutions. Regulatory considerations highly influence the market dynamics of POCT. For the safety and efficiency of point-of-care diagnostic devices, regulators around the world have established standards and guidelines. Getting approvals from regulators is a critical move for manufacturers because it influences product development timelines and entry into the market. The regulatory framework has also been evolving in line with peculiar challenges and opportunities presented by point-of-care testing. Also, the market dynamics of POCT depend on cost-effectiveness. In view of this, affordable point-of-care solutions are increasingly being sought as value-based healthcare gains ground. This aspect is crucial, especially in areas characterized by scarcity of resources or where healthcare decisions are greatly affected by the costs involved.

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    What is the CAGR for Point of Care Diagnostics Testing Market?

    The Point of Care Diagnostics/Testing Market can expand at 9.58% CAGR by 2035.

    Who are key players of the Point of Care Diagnostics Testing Market?

    Abbott Laboratories (US),Siemens Healthineers GmbH (Germany),Chembio Diagnostics, Inc.(US),Hoffmann-La Roche Ltd (Switzerland),Johnson & Johnson Services, Inc. (US),Becton, Dickinson and Company (US),Danaher Corporation (US),PTS Diagnostics (US),Nova Biomedical (US),QuidelCorporation (US) Are the key players of market

    What is the valuation of the Point of Care Diagnostics Testing Market?

    By 2035, the Point of Care Diagnostics/Testing Market value can exceed USD 157.87 Billion.

    What is the Point of Care Diagnostics Testing Market driver?

    Increasing demand for COVID-19 POC test kits is driving the Point of Care Diagnostics/Testing Market.

    What is the Point of Care Diagnostics Testing Market restrain?

    Increases the potential of rapid medical diagnosis restrain the Point of Care Diagnostics/Testing Market.

    Market Summary

    As per MRFR analysis, the Point of Care Diagnostics Testing Market was estimated at 57.71 USD Billion in 2024. The Point of Care Diagnostics Testing industry is projected to grow from 63.24 USD Billion in 2025 to 157.87 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 9.58 during the forecast period 2025 - 2035.

    Key Market Trends & Highlights

    The Point of Care Diagnostics Testing Market is experiencing robust growth driven by technological advancements and a shift towards decentralized healthcare.

    • Technological advancements are enhancing the accuracy and speed of point of care diagnostics, particularly in glucose monitoring.
    • The demand for decentralized testing is rising, especially in the Asia-Pacific region, as patients seek more accessible healthcare solutions.
    • Personalized medicine is gaining traction, influencing the development of tailored diagnostic tests in hospitals and clinics.
    • Key market drivers include technological innovations in point of care diagnostics and the rising prevalence of chronic diseases, which are shaping market dynamics.

    Market Size & Forecast

    2024 Market Size 57.71 (USD Billion)
    2035 Market Size 157.87 (USD Billion)
    CAGR (2025 - 2035) 9.58%
    Largest Regional Market Share in 2024 North America

    Major Players

    <p>Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Danaher Corporation (US), Thermo Fisher Scientific (US), Becton Dickinson and Company (US), Cepheid (US), Quidel Corporation (US), Hologic, Inc. (US)</p>

    Market Trends

    The Point of Care Diagnostics Testing Market is currently experiencing a transformative phase, characterized by rapid advancements in technology and an increasing demand for immediate diagnostic solutions. This market encompasses a wide array of testing devices and methodologies that facilitate quick results, often at the site of patient care. The growing emphasis on personalized medicine and the need for efficient healthcare delivery systems are driving innovations in this sector. Furthermore, the integration of digital health technologies, such as telemedicine and mobile health applications, appears to enhance the accessibility and efficiency of point-of-care testing, thereby expanding its reach across various healthcare settings. In addition, the Point of Care Diagnostics Testing Market is likely to benefit from the rising prevalence of chronic diseases and the aging population, which necessitate regular monitoring and timely interventions. The shift towards decentralized healthcare models, where testing occurs outside traditional laboratory environments, suggests a significant change in how healthcare services are delivered. As stakeholders continue to invest in research and development, the market is poised for sustained growth, with new products and solutions emerging to meet the evolving needs of patients and healthcare providers alike.

    Technological Advancements

    The Point of Care Diagnostics Testing Market is witnessing a surge in technological innovations, particularly in the development of portable and user-friendly devices. These advancements facilitate rapid testing and improve accuracy, thereby enhancing patient outcomes. The integration of artificial intelligence and machine learning into diagnostic tools is also becoming more prevalent, allowing for more precise interpretations of results.

    Increased Demand for Decentralized Testing

    There is a notable shift towards decentralized testing solutions within the Point of Care Diagnostics Testing Market. This trend is driven by the need for immediate results and the convenience of testing in non-traditional settings, such as homes and remote locations. As healthcare systems adapt to this model, the market is likely to expand, catering to a broader range of patient needs.

    Focus on Personalized Medicine

    The emphasis on personalized medicine is reshaping the Point of Care Diagnostics Testing Market. Tailoring diagnostic tests to individual patient profiles enhances treatment efficacy and fosters better health management. This trend indicates a growing recognition of the importance of individualized care, which is expected to influence product development and market strategies.

    <p>The Global Point of Care Diagnostics Testing Market is poised for substantial growth, driven by advancements in technology and an increasing demand for rapid diagnostic solutions in various healthcare settings.</p>

    U.S. Food and Drug Administration (FDA)

    Point of Care Diagnostics Testing Market Market Drivers

    Rising Prevalence of Chronic Diseases

    The increasing prevalence of chronic diseases is a significant driver for the Point of Care Diagnostics Testing Market. Conditions such as diabetes, cardiovascular diseases, and respiratory disorders necessitate regular monitoring and timely interventions. As the global population ages, the demand for rapid diagnostic solutions that can be administered at home or in outpatient settings is likely to rise. Market data suggests that the incidence of diabetes alone is expected to reach 700 million cases by 2045, underscoring the urgent need for effective point of care testing solutions. This trend not only emphasizes the importance of early detection but also highlights the potential for point of care diagnostics to improve patient outcomes through timely treatment. Consequently, healthcare providers are increasingly adopting these technologies to enhance patient management and reduce healthcare costs.

    Shift Towards Decentralized Healthcare

    The Point of Care Diagnostics Testing Market is witnessing a notable shift towards decentralized healthcare models. This transformation is driven by the need for accessible and efficient healthcare services, particularly in remote or underserved areas. Decentralized testing allows for immediate results, reducing the need for patients to travel to centralized laboratories. Recent statistics indicate that the market for decentralized diagnostics is expected to grow at a compound annual growth rate of 10% over the next five years. This growth is fueled by the increasing adoption of telemedicine and home healthcare services, which are becoming integral to modern healthcare delivery. As a result, point of care diagnostics are positioned to play a crucial role in facilitating timely medical interventions and improving overall healthcare accessibility.

    Increased Focus on Preventive Healthcare

    The Point of Care Diagnostics Testing Market is significantly influenced by the growing emphasis on preventive healthcare. As healthcare systems worldwide shift from reactive to proactive approaches, the demand for early detection and monitoring tools is escalating. Preventive diagnostics enable healthcare providers to identify potential health issues before they escalate, thereby reducing the burden on healthcare systems. Market analysis indicates that the preventive healthcare market is projected to reach USD 200 billion by 2027, with point of care testing being a vital component. This trend is further supported by public health initiatives aimed at promoting regular health screenings and awareness campaigns. Consequently, the integration of point of care diagnostics into routine healthcare practices is likely to enhance patient engagement and foster a culture of preventive care.

    Regulatory Support and Reimbursement Policies

    The Point of Care Diagnostics Testing Market is benefiting from favorable regulatory support and evolving reimbursement policies. Governments and health authorities are increasingly recognizing the value of point of care testing in improving healthcare outcomes and reducing costs. Recent policy changes have streamlined the approval processes for new diagnostic devices, facilitating quicker market entry. Additionally, reimbursement frameworks are adapting to include point of care tests, making them more financially viable for healthcare providers. This regulatory environment is expected to encourage innovation and investment in point of care diagnostics, as evidenced by the projected growth of the market, which is anticipated to reach USD 60 billion by 2028. Such supportive measures are likely to enhance the adoption of point of care testing across various healthcare settings, ultimately benefiting patients and providers alike.

    Technological Innovations in Point of Care Diagnostics

    The Point of Care Diagnostics Testing Market is experiencing a surge in technological innovations that enhance testing accuracy and speed. Advancements in microfluidics, biosensors, and portable devices are transforming traditional diagnostic methods. For instance, the integration of artificial intelligence in diagnostic tools is streamlining data analysis, leading to quicker decision-making. According to recent data, the market for point of care testing devices is projected to reach USD 50 billion by 2026, driven by these technological advancements. Furthermore, the development of multiplex testing capabilities allows for simultaneous detection of multiple pathogens, which is particularly beneficial in managing infectious diseases. This trend indicates a shift towards more efficient and user-friendly diagnostic solutions, making them increasingly accessible in various healthcare settings.

    Market Segment Insights

    By Product: Glucose Monitoring (Largest) vs. Infectious Disease Testing (Fastest-Growing)

    <p>In the Point of Care Diagnostics Testing Market, Glucose Monitoring stands out as the largest segment, capturing a substantial share of the market with its widespread use in managing diabetes. Other significant segments include Cardiometabolic Monitoring and Coagulation Monitoring; however, their market shares are comparatively smaller. On the other hand, Infectious Disease Testing is emerging rapidly, driven by recent global health challenges, highlighting the demand for quick and reliable testing methods among healthcare providers and patients alike.</p>

    <p>Glucose Monitoring (Dominant) vs. Infectious Disease Testing (Emerging)</p>

    <p>Glucose Monitoring is a well-established segment in the Point of Care Diagnostics Testing Market, primarily utilized by individuals with diabetes for managing blood sugar levels. Its dominance is fueled by technological advancements, such as continuous glucose monitoring systems that provide real-time data, enhancing patient compliance and outcomes. Conversely, Infectious Disease Testing is a rapidly emerging segment that has gained momentum, especially due to the urgent need for rapid testing solutions following global health crises. This segment encompasses innovations in testing methodologies and increased accessibility, focusing on delivering swift and accurate results for a wider array of infectious diseases, thus positioning it as a crucial player in the market.</p>

    By End User: Hospitals & Clinics (Largest) vs. Homecare/Self Testing (Fastest-Growing)

    <p>In the Point of Care Diagnostics Testing Market, hospitals and clinics stand out as the largest segment, owing to their significant patient footfall and increasing demand for quick diagnostic solutions. Diagnostic centers follow closely, providing specialized services that cater to diverse testing needs. Meanwhile, homecare/self-testing is gaining traction among consumers who prefer convenience and immediate results, particularly in the wake of the growing emphasis on remote healthcare.</p>

    <p>End User: Hospitals & Clinics (Dominant) vs. Homecare/Self Testing (Emerging)</p>

    <p>Hospitals and clinics dominate the Point of Care Diagnostics Testing Market due to their established infrastructure and ability to manage high patient volumes efficiently. They frequently utilize advanced diagnostic technologies to facilitate timely decision-making and improve patient outcomes. On the other hand, homecare/self-testing is an emerging segment characterized by its accessibility and user-friendly nature, appealing primarily to health-conscious individuals seeking to monitor their conditions privately. This segment is witnessing rapid growth, driven by innovations in testing kits and the rising demand for at-home health solutions, ultimately reshaping traditional healthcare delivery.</p>

    By Mode of Purchase: OTC Testing Products (Largest) vs. Prescription-based Testing Products (Fastest-Growing)

    <p>In the Point of Care Diagnostics Testing Market, the distribution of market share between OTC testing products and prescription-based testing products reveals a clear dominance of OTC products. OTC testing products cater to the growing demand for self-testing and at-home diagnostics, which is increasingly preferred by consumers seeking convenience and accessibility. Prescription-based testing products, while smaller in market share, are rapidly gaining traction due to their specific applications and trusted results, favored by healthcare providers for accuracy and reliability. The growth trends in this segment are indicative of evolving consumer preferences and advancements in technology. The increase in health awareness and the shift towards personalized healthcare solutions drive the demand for OTC testing products, which are positioned for immediate use without needing a healthcare provider. Conversely, prescription-based testing products are experiencing a surge in demand as healthcare systems emphasize more accurate diagnostics and a move towards comprehensive patient management, signaling an emerging trend that is likely to expand in the coming years.</p>

    <p>Mode of Purchase: OTC Testing Products (Dominant) vs. Prescription-based Testing Products (Emerging)</p>

    <p>OTC testing products have established themselves as the dominant force in the Point of Care Diagnostics Testing Market, thanks to their ease of use and accessibility. These products empower consumers to take charge of their health, offering the advantage of timely testing without the need for medical appointments. Their popularity is reinforced by a wide range of applications, including disease screening and health monitoring. In contrast, prescription-based testing products are emerging rapidly, showcasing a different set of characteristics. They are characterized by their accuracy and are often used in clinical settings where precise diagnostics are crucial. These products are supported by healthcare professionals and are gaining acceptance among patients who trust their reliability. Together, these two segments highlight a comprehensive approach to diagnostics, catering to diverse consumer needs.</p>

    By Platform: Immunoassays (Largest) vs. Molecular Diagnostics (Fastest-Growing)

    <p>In the Point of Care Diagnostics Testing Market, the distribution of market share among the key platforms reveals that Immunoassays hold the largest portion of the market. This is largely due to their established use in various diagnostics applications, making them a preferred choice for healthcare providers. In contrast, Molecular Diagnostics, while smaller in market share, are rapidly gaining traction owing to advancements in technology and increasing demand for precision testing. Dipsticks, although recognized, remain at the periphery of this growth in terms of overall market share compared to the other two platforms.</p>

    <p>Immunoassays (Dominant) vs. Dipsticks (Emerging)</p>

    <p>Immunoassays dominate the Point of Care Diagnostics Testing Market due to their reliability, ease of use, and versatility across various medical conditions. They are highly sought after for their capacity to provide rapid and accurate results, which is paramount in urgent care settings. Dipsticks, on the other hand, represent an emerging platform that, while historically used for basic diagnostics like glucose monitoring, are innovating with new applications. They offer low-cost, portable solutions but lack the comprehensive capabilities of Immunoassays, positioning them as a supplementary rather than primary choice in the diagnostics landscape.</p>

    Get more detailed insights about Point of Care Diagnostics Testing Market Research Report - Global Forecast till 2035

    Regional Insights

    North America : Leading Innovation and Adoption

    North America is the largest market for Point of Care Diagnostics Testing, holding approximately 45% of the global market share. The region's growth is driven by increasing demand for rapid diagnostic tests, technological advancements, and supportive regulatory frameworks. The COVID-19 pandemic has further accelerated the adoption of point-of-care testing, leading to significant investments in healthcare infrastructure and innovation. The United States is the primary contributor to this market, with key players like Abbott Laboratories, Roche Diagnostics, and Thermo Fisher Scientific leading the charge. The competitive landscape is characterized by continuous innovation and strategic partnerships among these companies. The presence of advanced healthcare facilities and a focus on personalized medicine further bolster the market's growth in this region.

    Europe : Regulatory Support and Growth

    Europe is the second-largest market for Point of Care Diagnostics Testing, accounting for approximately 30% of the global market share. The region benefits from stringent regulatory standards that ensure the quality and reliability of diagnostic tests. Increasing prevalence of chronic diseases and a growing emphasis on preventive healthcare are key drivers of market growth. The European Union's initiatives to enhance healthcare accessibility also play a significant role in shaping the market landscape. Leading countries in this region include Germany, France, and the UK, where companies like Siemens Healthineers and Roche Diagnostics are prominent. The competitive environment is marked by innovation and collaboration among various stakeholders, including healthcare providers and technology firms. The presence of robust healthcare systems and a focus on research and development further enhance the market's potential.

    Asia-Pacific : Rapid Growth and Expansion

    Asia-Pacific is witnessing rapid growth in the Point of Care Diagnostics Testing market, holding approximately 20% of the global market share. The region's growth is fueled by rising healthcare expenditures, increasing awareness of early disease detection, and a growing aging population. Additionally, government initiatives aimed at improving healthcare infrastructure and access to diagnostic services are significant catalysts for market expansion. Countries like China, India, and Japan are leading the charge, with a mix of local and international players such as Danaher Corporation and Becton Dickinson making significant inroads. The competitive landscape is evolving, with a focus on affordable and accessible testing solutions. The region's diverse healthcare needs and varying regulatory environments present both challenges and opportunities for market participants.

    Middle East and Africa : Untapped Potential and Growth

    The Middle East and Africa region is gradually emerging in the Point of Care Diagnostics Testing market, holding about 5% of the global market share. The growth is driven by increasing investments in healthcare infrastructure, rising prevalence of infectious diseases, and a growing focus on improving healthcare access. Government initiatives aimed at enhancing diagnostic capabilities are also contributing to market development in this region. Leading countries include South Africa, UAE, and Saudi Arabia, where local and international companies are beginning to establish a foothold. The competitive landscape is characterized by a mix of established players and new entrants, focusing on innovative solutions tailored to local needs. The region's unique challenges, such as varying healthcare standards and economic disparities, present both hurdles and opportunities for growth.

    Key Players and Competitive Insights

    The Point of Care Diagnostics Testing Market is characterized by a dynamic competitive landscape, driven by technological advancements and an increasing demand for rapid diagnostic solutions. Key players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Siemens Healthineers (DE) are strategically positioned to leverage innovation and expand their market presence. Abbott Laboratories (US) focuses on enhancing its product portfolio through continuous innovation, particularly in the development of portable diagnostic devices. Meanwhile, Roche Diagnostics (CH) emphasizes strategic partnerships to bolster its capabilities in molecular diagnostics, thereby enhancing its competitive edge. Siemens Healthineers (DE) is actively pursuing digital transformation initiatives, integrating AI and data analytics into its diagnostic solutions, which positions it favorably in a market that increasingly values technological integration.

    The competitive structure of the Point of Care Diagnostics Testing Market appears moderately fragmented, with several key players vying for market share. Companies are adopting various business tactics, such as localizing manufacturing to reduce costs and optimize supply chains. This approach not only enhances operational efficiency but also allows for quicker response times to market demands. The collective influence of these major players shapes the market dynamics, as they continuously innovate and adapt to changing consumer needs and regulatory environments.

    In August 2025, Roche Diagnostics (CH) announced a strategic partnership with a leading telehealth provider to integrate its point-of-care testing solutions into remote healthcare services. This collaboration is significant as it expands Roche's reach into the telehealth sector, allowing for seamless integration of diagnostic testing with virtual consultations. Such a move not only enhances patient access to diagnostics but also positions Roche as a leader in the evolving landscape of integrated healthcare solutions.

    In September 2025, Abbott Laboratories (US) launched a new rapid diagnostic test for infectious diseases, which utilizes advanced molecular technology to deliver results in under 30 minutes. This innovation is crucial as it addresses the growing demand for quick and accurate testing solutions, particularly in outpatient settings. Abbott's focus on rapid diagnostics aligns with current healthcare trends that prioritize speed and efficiency, potentially solidifying its market position.

    In October 2025, Siemens Healthineers (DE) unveiled a new AI-driven analytics platform designed to enhance the accuracy and efficiency of point-of-care testing. This platform aims to provide healthcare professionals with real-time insights, thereby improving patient outcomes. The introduction of such technology reflects Siemens' commitment to integrating advanced analytics into its diagnostic offerings, which is likely to resonate well with healthcare providers seeking to enhance their operational capabilities.

    As of October 2025, the competitive trends in the Point of Care Diagnostics Testing Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in enhancing their technological capabilities and market reach. Looking ahead, competitive differentiation is expected to evolve, shifting from traditional price-based competition to a focus on innovation, technological advancement, and supply chain reliability. This transition underscores the importance of agility and responsiveness in a rapidly changing market environment.

    Key Companies in the Point of Care Diagnostics Testing Market market include

    Industry Developments

    • In June 2021,DCN Dx(US) acquired the pointofcare diagnostics development company PortaScience Inc. (US). This acquisition will expand the point of care product portfolio of the company.
    • In April 2021,the Indian Institute of Technology Kharagpur (India), an Indian engineering institute,launched a nucleic acid-based pointof care diagnostic devicefor COVID-19 diagnosis.
    • In April 2021,LumiraDx (US), a next-generation point of care diagnostics testing company,announced its merger with CA Healthcare Acquisition (CAHC) (US)in a deal worth USD 5 billion.
    • In March 2021, MatMaCorp (US) launched MYRTA, a handheld real-time POCPCR device for molecular diagnostics.
    • In March 2020, Abbott(US) launched the fastest available molecular pointofcare test to detect the coronavirus in less than 5 minutes.

    Future Outlook

    Point of Care Diagnostics Testing Market Future Outlook

    <p>The Point of Care Diagnostics Testing Market is projected to grow at a 9.58% CAGR from 2024 to 2035, driven by technological advancements, increasing demand for rapid testing, and rising healthcare expenditures.</p>

    New opportunities lie in:

    • <p>Development of portable diagnostic devices for remote areas</p>
    • <p>Integration of AI for enhanced diagnostic accuracy</p>
    • <p>Expansion of telehealth services incorporating POC testing</p>

    <p>By 2035, the market is expected to be robust, driven by innovation and increased accessibility.</p>

    Market Segmentation

    Point of Care Diagnostics Testing Market Product Outlook

    • Glucose Monitoring
    • Cardiometabolic Monitoring
    • Infectious Disease Testing
    • Coagulation Monitoring
    • Pregnancy & Fertility Testing
    • Hematology Testing
    • Cancer/Tumor Marker Testing
    • Urinalysis Testing
    • Cholesterol
    • Drugs-of-Abuse Testing

    Point of Care Diagnostics Testing Market End User Outlook

    • Hospitals & Clinics
    • Diagnostic Centers
    • Homecare/Self Testing

    Point of Care Diagnostics Testing Market Platform Outlook

    • Immunoassays
    • Molecular Diagnostics
    • Dipsticks

    Point of Care Diagnostics Testing Market Mode of Purchase Outlook

    • OTC Testing Products
    • Prescription-based testing products

    Report Scope

    MARKET SIZE 202457.71(USD Billion)
    MARKET SIZE 202563.24(USD Billion)
    MARKET SIZE 2035157.87(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR)9.58% (2024 - 2035)
    REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR2024
    Market Forecast Period2025 - 2035
    Historical Data2019 - 2024
    Market Forecast UnitsUSD Billion
    Key Companies ProfiledMarket analysis in progress
    Segments CoveredMarket segmentation analysis in progress
    Key Market OpportunitiesIntegration of artificial intelligence enhances accuracy and efficiency in the Point of Care Diagnostics Testing Market.
    Key Market DynamicsTechnological advancements and regulatory changes drive innovation and competition in the Point of Care Diagnostics Testing Market.
    Countries CoveredNorth America, Europe, APAC, South America, MEA

    Market Highlights

    Author

    Rahul Gotadki
    Assistant Manager

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM

    FAQs

    What is the CAGR for Point of Care Diagnostics Testing Market?

    The Point of Care Diagnostics/Testing Market can expand at 9.58% CAGR by 2035.

    Who are key players of the Point of Care Diagnostics Testing Market?

    Abbott Laboratories (US),Siemens Healthineers GmbH (Germany),Chembio Diagnostics, Inc.(US),Hoffmann-La Roche Ltd (Switzerland),Johnson &amp; Johnson Services, Inc. (US),Becton, Dickinson and Company (US),Danaher Corporation (US),PTS Diagnostics (US),Nova Biomedical (US),QuidelCorporation (US) Are the key players of market

    What is the valuation of the Point of Care Diagnostics Testing Market?

    By 2035, the Point of Care Diagnostics/Testing Market value can exceed USD 157.87 Billion.

    What is the Point of Care Diagnostics Testing Market driver?

    Increasing demand for COVID-19 POC test kits is driving the Point of Care Diagnostics/Testing Market.

    What is the Point of Care Diagnostics Testing Market restrain?

    Increases the potential of rapid medical diagnosis restrain the Point of Care Diagnostics/Testing Market.

    1. REPORT PROLOGUE
    2. MARKET INTRODUCTION
      1. Definition
      2. Scope of the Study
        1. Research Objective
        2. Assumptions
        3. Limitations
    3. RESEARCH METHODOLOGY
      1. Overview
      2. Data Mining
      3. Secondary Research
      4. Primary Research
        1. Primary Interviews and Information Gathering Process
        2. Breakdown of Primary Respondents
      5. Forecasting Cellulite Type
      6. Market Size Estimation
        1. Bottom-Up Approach
        2. Top-Down Approach
      7. Data Triangulation
      8. Validation
    4. MARKET DYNAMICS
      1. Overview
      2. Drivers
      3. Restraints
      4. Opportunities
    5. MARKET FACTOR ANALYSIS
      1. Porter’s Five Forces Analysis
        1. Bargaining Power of Suppliers
        2. Bargaining Power of Buyers
        3. Threat of New Entrants
        4. Threat of Substitutes
        5. Intensity of Rivalry
      2. Value Chain Analysis
      3. COVID-19 Impact Analysis
        1. Market Impact Analysis
        2. Impact on Supply Chain
        3. Regional Impact
        4. Opportunity and Threat Analysis
    6. GLOBAL Point of Care Diagnostics Testing MARKET, BY PRODUCT
      1. Overview
      2. Glucose Monitoring
    7. Market Estimates & Forecast, by Region, 2022–2030
    8. Market Estimates & Forecast, by Country, 2022–2030
    9. Strips
    10. Market Estimates & Forecast, by Region, 2022–2030
    11. Market Estimates & Forecast, by Country, 2022–2030
    12. Meters
    13. Market Estimates & Forecast, by Region, 2022–2030
    14. Market Estimates & Forecast, by Country, 2022–2030
    15. Lancets
    16. Market Estimates & Forecast, by Region, 2022–2030
    17. Market Estimates & Forecast, by Country, 2022–2030
      1. Cardiometabolic Monitoring
    18. Market Estimates & Forecast, by Region, 2022–2030
    19. Market Estimates & Forecast, by Country, 2022–2030
    20. Cardiac Marker Testing Products
    21. Market Estimates & Forecast, by Region, 2022–2030
    22. Market Estimates & Forecast, by Country, 2022–2030
    23. Blood Gas/Electrolyte Testing Products
    24. Market Estimates & Forecast, by Region, 2022–2030
    25. Market Estimates & Forecast, by Country, 2022–2030
    26. HbA1c Testing Products
    27. Market Estimates & Forecast, by Region, 2022–2030
    28. Market Estimates & Forecast, by Country, 2022–2030
      1. Infectious Disease Testing
    29. Market Estimates & Forecast, by Region, 2022–2030
    30. Market Estimates & Forecast, by Country, 2022–2030
    31. HIV Testing
    32. Market Estimates & Forecast, by Region, 2022–2030
    33. Market Estimates & Forecast, by Country, 2022–2030
    34. Respiratory Infection Testing
    35. Market Estimates & Forecast, by Region, 2022–2030
    36. Market Estimates & Forecast, by Country, 2022–2030
    37. Hepatitis Testing
    38. Market Estimates & Forecast, by Region, 2022–2030
    39. Market Estimates & Forecast, by Country, 2022–2030
    40. Sexually Transmitted Disease Testing
    41. Market Estimates & Forecast, by Region, 2022–2030
    42. Market Estimates & Forecast, by Country, 2022–2030
    43. Others
    44. Market Estimates & Forecast, by Region, 2022–2030
    45. Market Estimates & Forecast, by Country, 2022–2030
      1. Coagulation Monitoring
    46. Market Estimates & Forecast, by Region, 2022–2030
    47. Market Estimates & Forecast, by Country, 2022–2030
    48. PT/INR Testing
    49. Market Estimates & Forecast, by Region, 2022–2030
    50. Market Estimates & Forecast, by Country, 2022–2030
    51. ACT/APTT Testing
    52. Market Estimates & Forecast, by Region, 2022–2030
    53. Market Estimates & Forecast, by Country, 2022–2030
      1. Pregnancy & Fertility Testing
    54. Market Estimates & Forecast, by Region, 2022–2030
    55. Market Estimates & Forecast, by Country, 2022–2030
      1. Hematology Testing
    56. Market Estimates & Forecast, by Region, 2022–2030
    57. Market Estimates & Forecast, by Country, 2022–2030
      1. Cancer/Tumor Marker Testing
    58. Market Estimates & Forecast, by Region, 2022–2030
    59. Market Estimates & Forecast, by Country, 2022–2030
      1. Urinalysis Testing
    60. Market Estimates & Forecast, by Region, 2022–2030
    61. Market Estimates & Forecast, by Country, 2022–2030
      1. Cholesterol
    62. Market Estimates & Forecast, by Region, 2022–2030
    63. Market Estimates & Forecast, by Country, 2022–2030
      1. Drugs-of-Abuse Testing
    64. Market Estimates & Forecast, by Region, 2022–2030
    65. Market Estimates & Forecast, by Country, 2022–2030
      1. Others
    66. Market Estimates & Forecast, by Region, 2022–2030
    67. Market Estimates & Forecast, by Country, 2022–2030
    68. GLOBAL Point of Care Diagnostics Testing MARKET, BY END USER
      1. Overview
      2. Hospitals & Clinics
    69. Market Estimates & Forecast, by Region, 2022–2030
    70. Market Estimates & Forecast, by Country, 2022–2030
      1. Diagnostic Centers
    71. Market Estimates & Forecast, by Region, 2022–2030
    72. Market Estimates & Forecast, by Country, 2022–2030
      1. Homecare/Self Testing
    73. Market Estimates & Forecast, by Region, 2022–2030
    74. Market Estimates & Forecast, by Country, 2022–2030
      1. Others
    75. Market Estimates & Forecast, by Region, 2022–2030
    76. Market Estimates & Forecast, by Country, 2022–2030
    77. GLOBAL Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE
      1. Overview
      2. OTC Testing Products
    78. Market Estimates & Forecast, by Region, 2022–2030
    79. Market Estimates & Forecast, by Country, 2022–2030
      1. Prescription-based testing products
    80. Market Estimates & Forecast, by Region, 2022–2030
    81. Market Estimates & Forecast, by Country, 2022–2030
    82. GLOBAL Point of Care Diagnostics Testing MARKET, BY PLATFORM
      1. Overview
      2. Immunoassays
    83. Market Estimates & Forecast, by Region, 2022–2030
    84. Market Estimates & Forecast, by Country, 2022–2030
      1. Dipsticks
    85. Market Estimates & Forecast, by Region, 2022–2030
    86. Market Estimates & Forecast, by Country, 2022–2030
      1. Molecular Diagnostics
    87. Market Estimates & Forecast, by Region, 2022–2030
    88. Market Estimates & Forecast, by Country, 2022–2030
      1. Others
    89. Market Estimates & Forecast, by Region, 2022–2030
    90. Market Estimates & Forecast, by Country, 2022–2030
    91. GLOBAL Point of Care Diagnostics Testing MARKET, BY REGION
      1. Overview
      2. North America
        1. US
        2. Canada
      3. Europe
        1. Germany
        2. France
        3. UK
        4. Italy
        5. Spain
        6. Rest of Europe
      4. Asia-Pacific
        1. China
        2. India
        3. Japan
        4. South Korea
        5. Australia
        6. Rest of Asia-Pacific
      5. Rest of the World
        1. Middle East
        2. Africa
        3. Latin America
    92. COMPANY LANDSCAPE
      1. Overview
      2. Competitive Analysis
      3. Market Share Analysis
      4. Major Growth Strategy in the Global Point of Care Diagnostics Testing Market
      5. Competitive Benchmarking
      6. Leading Players in Terms of Number of Developments in the Global Point of Care Diagnostics Testing Market
      7. Key developments and Growth Strategies
        1. New ProductLaunch/Service Deployment
        2. Merger &Acquisitions
        3. Joint Ventures
      8. Major Players Financial Matrix
        1. Sales & Operating Income, 2020
        2. Major Players R&D Expenditure, 2020
    93. COMPANY PROFILES
      1. Abbott Laboratories
        1. Company Overview
        2. Product Offered
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      2. Siemens Healthineers GmbH
        1. Company Overview
        2. Product Offered
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      3. Chembio Diagnostics, Inc.
        1. Company Overview
        2. Product Offered
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      4. F. Hoffmann-La Roche Ltd
        1. Company Overview
        2. Product Offered
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      5. Johnson & Johnson Services, Inc.
        1. Company Overview
        2. Product Offered
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      6. Becton, Dickinson and Company
        1. Company Overview
        2. Product Offered
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      7. Danaher Corporation
        1. Company Overview
        2. Product Offered
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      8. PTS Diagnostics
        1. Company Overview
        2. Product Offered
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      9. Nova Biomedical
        1. Company Overview
        2. Product Offered
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      10. Quidel Corporation
        1. Company Overview
        2. Product Offered
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      11. Sekisui Diagnostics
        1. Company Overview
        2. Product Offered
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      12. Trinity Biotech
        1. Company Overview
        2. Product Offered
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      13. AccuBioTech Co., Ltd.
        1. Company Overview
        2. Product Offered
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      14. Instrumentation Laboratory Company (Werfen)
        1. Company Overview
        2. Product Offered
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      15. EKF Diagnostics Holdings plc
        1. Company Overview
        2. Product Offered
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
    94. APPENDIX
      1. References
      2. Related Reports
    95. LIST OF TABLES
    96. GLOBAL Point of Care Diagnostics Testing MARKET SYNOPSIS, 2022–2030
    97. GLOBAL Point of Care Diagnostics Testing MARKET ESTIMATES &FORECAST, 2022–2030(USD MILLION)
    98. GLOBAL Point of Care Diagnostics Testing MARKET, BYPRODUCT, 2022–2030 (USD MILLION)
    99. GLOBAL Point of Care Diagnostics Testing MARKET, BY END USER,2022–2030 (USD MILLION)
    100. GLOBAL Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    101. GLOBAL Point of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    102. NORTH AMERICA OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    103. NORTH AMERICAPoint of Care Diagnostics Testing MARKET, BY END USER,2022–2030 (USD MILLION)
    104. NORTH AMERICAPoint of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    105. NORTH AMERICAPoint of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    106. US: Point of Care Diagnostics Testing MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    107. US Point of Care Diagnostics Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    108. US: Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    109. US: Point of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    110. CANADA: Point of Care Diagnostics Testing MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    111. CANADA Point of Care Diagnostics Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    112. CANADA: Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    113. CANADA: Point of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    114. EUROPE: Point of Care Diagnostics Testing MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    115. EUROPE: Point of Care Diagnostics Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    116. EUROPE: Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    117. EUROPE: Point of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    118. GERMANY: Point of Care Diagnostics Testing MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    119. GERMANY: Point of Care Diagnostics Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    120. GERMANY: Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    121. GERMANY: Point of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    122. FRANCE: Point of Care Diagnostics Testing MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    123. FRANCE: Point of Care Diagnostics Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    124. FRANCE: Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    125. FRANCE: Point of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    126. UK: Point of Care Diagnostics Testing MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    127. UK: Point of Care Diagnostics Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    128. UK: Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    129. UK: Point of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    130. ITALY: Point of Care Diagnostics Testing MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    131. ITALY: Point of Care Diagnostics Testing MARKET, BY END USER2022–2030 (USD MILLION)
    132. ITALY: Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    133. ITALY: Point of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    134. SPAIN: Point of Care Diagnostics Testing MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    135. SPAIN: Point of Care Diagnostics Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    136. SPAIN: Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    137. SPAIN: Point of Care Diagnostics Testing MARKET, BYPLATFORM2022–2030 (USD MILLION)
    138. REST OF EUROPE: Point of Care Diagnostics Testing MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    139. REST OF EUROPE: Point of Care Diagnostics Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    140. REST OF EUROPE: Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    141. REST OF EUROPE: Point of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    142. ASIA-PACIFIC: Point of Care Diagnostics Testing MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    143. ASIA-PACIFIC: Point of Care Diagnostics Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    144. ASIA-PACIFIC: Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    145. ASIA-PACIFIC: Point of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    146. CHINA: Point of Care Diagnostics Testing MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    147. CHINA: Point of Care Diagnostics Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    148. CHINA: Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    149. CHINA: Point of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    150. INDIA: Point of Care Diagnostics Testing MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    151. INDIA: Point of Care Diagnostics Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    152. INDIA: Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    153. INDIA: Point of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    154. JAPAN: Point of Care Diagnostics Testing MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    155. JAPAN: Point of Care Diagnostics Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    156. JAPAN: Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    157. JAPAN: Point of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    158. SOUTH KOREA: Point of Care Diagnostics Testing MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    159. SOUTH KOREA: Point of Care Diagnostics Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    160. SOUTH KOREA: Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    161. SOUTH KOREA: Point of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    162. AUSTRALIA: Point of Care Diagnostics Testing MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    163. AUSTRALIA: Point of Care Diagnostics Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    164. AUSTRALIA: Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    165. AUSTRALIA: Point of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    166. REST OF ASIA-PACIFIC: Point of Care Diagnostics Testing MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    167. REST OF ASIA-PACIFIC: Point of Care Diagnostics Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    168. REST OF ASIA-PACIFIC: Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    169. REST OF ASIA-PACIFIC: Point of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    170. REST OF WORLD: Point of Care Diagnostics Testing MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    171. REST OF WORLD: Point of Care Diagnostics Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    172. REST OF WORLD: Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    173. REST OF WORLD: Point of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    174. MIDDLE EAST: Point of Care Diagnostics Testing MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    175. MIDDLE EAST: Point of Care Diagnostics Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    176. MIDDLE EAST: Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    177. MIDDLE EAST: Point of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    178. AFRICA: Point of Care Diagnostics Testing MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    179. AFRICA: Point of Care Diagnostics Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    180. AFRICA: Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    181. AFRICA: Point of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    182. LATIN AMERICA: Point of Care Diagnostics Testing MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    183. LATIN AMERICA: Point of Care Diagnostics Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    184. LATIN AMERICA: Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    185. LATIN AMERICA: Point of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    186. LIST OF FIGURES
    187. RESEARCH PROCESS
    188. MARKET STRUCTURE FOR THE GLOBAL POINT OF CAREDIAGNOSTICS/TESTING MARKET
    189. MARKET DYNAMICS FOR THE GLOBAL Point of Care Diagnostics Testing MARKET
    190. GLOBAL Point of Care Diagnostics Testing MARKET SHARE, BY PRODUCT, 2020 (%)
    191. GLOBAL Point of Care Diagnostics Testing MARKET SHARE, BY END USER, 2020 (%)
    192. GLOBAL Point of Care Diagnostics Testing MARKET SHARE, BY MODE OF PURCHASE, 2020 (%)
    193. GLOBAL Point of Care Diagnostics Testing MARKET SHARE, BY PLATFORM, 2020 (%)
    194. GLOBAL Point of Care Diagnostics Testing MARKET SHARE, BY REGION, 2020 (%)
    195. NORTH AMERICAPoint of Care Diagnostics Testing MARKET SHARE, BY PRODUCT, 2020 (%)
    196. NORTH AMERICAPoint of Care Diagnostics Testing MARKET SHARE, BY END USER, 2020 (%)
    197. NORTH AMERICAPoint of Care Diagnostics Testing MARKET SHARE, BY MODE OF PURCHASE, 2020 (%)
    198. NORTH AMERICAPoint of Care Diagnostics Testing MARKET SHARE, BY PLATFORM, 2020 (%)
    199. EUROPEPoint of Care Diagnostics Testing MARKET SHARE, BY PRODUCT, 2020 (%)
    200. EUROPEPoint of Care Diagnostics Testing MARKET SHARE, BY END USER, 2020 (%)
    201. EUROPEPoint of Care Diagnostics Testing MARKET SHARE, BY MODE OF PURCHASE, 2020 (%)
    202. EUROPEPoint of Care Diagnostics Testing MARKET SHARE, BY PLATFORM, 2020 (%)
    203. ASIA-PACIFICPoint of Care Diagnostics Testing MARKET SHARE, BY PRODUCT, 2020 (%)
    204. ASIA-PACIFICPoint of Care Diagnostics Testing MARKET SHARE, BY END USER, 2020 (%)
    205. ASIA-PACIFICPoint of Care Diagnostics Testing MARKET SHARE, BY MODE OF PURCHASE, 2020 (%)
    206. ASIA-PACIFICPoint of Care Diagnostics Testing MARKET SHARE, BY PLATFORM, 2020 (%)
    207. REST OF THE WORLDPoint of Care Diagnostics Testing MARKET SHARE, BY PRODUCT, 2020 (%)
    208. REST OF THE WORLD Point of Care Diagnostics Testing MARKET SHARE, BY END USER, 2020 (%)
    209. REST OF THE WORLDPoint of Care Diagnostics Testing MARKET SHARE, BY MODE OF PURCHASE, 2020 (%)
    210. REST OF THE WORLD Point of Care Diagnostics Testing MARKET SHARE, BY PLATFORM, 2020 (%)
    211. ABBOTT LABORATORIES .: KEY FINANCIALS
    212. ABBOTT LABORATORIES : SEGMENTAL REVENUE
    213. ABBOTT LABORATORIES : REGIONAL REVENUE
    214. SIEMENS HEALTHINEERS GMBH : KEY FINANCIALS
    215. SIEMENS HEALTHINEERS GMBH : SEGMENTAL REVENUE
    216. SIEMENS HEALTHINEERS GMBH : REGIONAL REVENUE
    217. CHEMBIO DIAGNOSTICS, INC. : KEY FINANCIALS
    218. CHEMBIO DIAGNOSTICS, INC. : SEGMENTAL REVENUE
    219. CHEMBIO DIAGNOSTICS, INC. : REGIONAL REVENUE
    220. F. HOFFMANN-LA ROCHE LTD.: KEY FINANCIALS
    221. F. HOFFMANN-LA ROCHE LTD.: SEGMENTAL REVENUE
    222. F. HOFFMANN-LA ROCHE LTD.: REGIONAL REVENUE
    223. JOHNSON & JOHNSON SERVICES, INC. : KEY FINANCIALS
    224. JOHNSON & JOHNSON SERVICES, INC. : SEGMENTAL REVENUE
    225. JOHNSON & JOHNSON SERVICES, INC. : REGIONAL REVENUE
    226. BECTON, DICKINSON AND COMPANY : KEY FINANCIALS
    227. BECTON, DICKINSON AND COMPANY : SEGMENTAL REVENUE
    228. BECTON, DICKINSON AND COMPANY : REGIONAL REVENUE
    229. DANAHER CORPORATION : KEY FINANCIALS
    230. DANAHER CORPORATION : SEGMENTAL REVENUE
    231. DANAHER CORPORATION : REGIONAL REVENUE
    232. PTS DIAGNOSTICS: KEY FINANCIALS
    233. PTS DIAGNOSTICS: SEGMENTAL REVENUE
    234. PTS DIAGNOSTICS: REGIONAL REVENUE
    235. NOVA BIOMEDICAL : KEY FINANCIALS
    236. NOVA BIOMEDICAL : SEGMENTAL REVENUE
    237. NOVA BIOMEDICAL : REGIONAL REVENUE
    238. QUIDEL CORPORATION : KEY FINANCIALS
    239. QUIDEL CORPORATION : SEGMENTAL REVENUE
    240. QUIDEL CORPORATION : REGIONAL REVENUE
    241. SEKISUI DIAGNOSTICS : KEY FINANCIALS
    242. SEKISUI DIAGNOSTICS : SEGMENTAL REVENUE
    243. SEKISUI DIAGNOSTICS : REGIONAL REVENUE
    244. TRINITY BIOTECH : KEY FINANCIALS
    245. TRINITY BIOTECH : SEGMENTAL REVENUE
    246. TRINITY BIOTECH : REGIONAL REVENUE
    247. ACCUBIOTECH CO., LTD.: KEY FINANCIALS
    248. ACCUBIOTECH CO., LTD.: SEGMENTAL REVENUE
    249. ACCUBIOTECH CO., LTD.: REGIONAL REVENUE
    250. INSTRUMENTATION LABORATORY COMPANY (WERFEN): KEY FINANCIALS
    251. INSTRUMENTATION LABORATORY COMPANY (WERFEN): SEGMENTAL REVENUE
    252. INSTRUMENTATION LABORATORY COMPANY (WERFEN): REGIONAL REVENUE
    253. EKF DIAGNOSTICS HOLDINGS PLC: KEY FINANCIALS
    254. EKF DIAGNOSTICS HOLDINGS PLC: SEGMENTAL REVENUE
    255. EKF DIAGNOSTICS HOLDINGS PLC: REGIONAL REVENUE
      1. "

    Point of Care Diagnostics Testing Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization
    Direct Access to Analyst
    Deliverable Format
    Platform Access
    Discount on Next Purchase 10% 15% 15%
    Printable Versions